Author
Listed:
- Gemma Martinez-Rivas
(University of Limoges, CRIBL lab, team 3 BioPIC
French National Reference Centre for AL Amyloidosis and Other Monoclonal IG Deposition Diseases, University Hospital)
- Maria Victoria Ayala
(University of Limoges, CRIBL lab, team 3 BioPIC
French National Reference Centre for AL Amyloidosis and Other Monoclonal IG Deposition Diseases, University Hospital)
- Sebastien Bender
(University of Limoges, CRIBL lab, team 3 BioPIC
French National Reference Centre for AL Amyloidosis and Other Monoclonal IG Deposition Diseases, University Hospital)
- Gilles Roussine Codo
(University of Limoges, CRIBL lab, team 3 BioPIC
French National Reference Centre for AL Amyloidosis and Other Monoclonal IG Deposition Diseases, University Hospital)
- Weronika Karolina Swiderska
(University of Limoges, CRIBL lab, team 3 BioPIC
French National Reference Centre for AL Amyloidosis and Other Monoclonal IG Deposition Diseases, University Hospital)
- Alessio Lampis
(University of Limoges, CRIBL lab, team 3 BioPIC
French National Reference Centre for AL Amyloidosis and Other Monoclonal IG Deposition Diseases, University Hospital)
- Laura Pedroza
(Centre for Medical Biotechnology)
- Melisa Merdanovic
(Centre for Medical Biotechnology)
- Pierre Sicard
(universityof Montpellier)
- Emilie Pinault
(University of Limoges)
- Laurence Richard
(University Hospital)
- Francesca Lavatelli
(University of Pavia
Fondazione IRCCS Policlinico San Matteo)
- Sofia Giorgetti
(University of Pavia
Fondazione IRCCS Policlinico San Matteo)
- Diana Canetti
(University College London)
- Alexa Rinsant
(University Hospital)
- Sihem Kaaki
(University Hospital)
- Cécile Ory
(University Hospital)
- Christelle Oblet
(University of Limoges, CRIBL lab, team 3 BioPIC)
- Justine Pollet
(University of Limoges, CRIBL lab, team 3 BioPIC)
- Eyad Naser
(University Hospital Essen)
- Alexander Carpinteiro
(University Hospital Essen)
- Muriel Roussel
(University of Limoges, CRIBL lab, team 3 BioPIC
French National Reference Centre for AL Amyloidosis and Other Monoclonal IG Deposition Diseases, University Hospital)
- Vincent Javaugue
(University of Limoges, CRIBL lab, team 3 BioPIC
French National Reference Centre for AL Amyloidosis and Other Monoclonal IG Deposition Diseases, University Hospital
University Hospital)
- Arnaud Jaccard
(University of Limoges, CRIBL lab, team 3 BioPIC
French National Reference Centre for AL Amyloidosis and Other Monoclonal IG Deposition Diseases, University Hospital)
- Amélie Bonaud
(University of Limoges, CRIBL lab, team 3 BioPIC
French National Reference Centre for AL Amyloidosis and Other Monoclonal IG Deposition Diseases, University Hospital)
- Laurent Delpy
(University of Limoges, CRIBL lab, team 3 BioPIC
French National Reference Centre for AL Amyloidosis and Other Monoclonal IG Deposition Diseases, University Hospital)
- Michael Ehrmann
(Centre for Medical Biotechnology)
- Frank Bridoux
(University of Limoges, CRIBL lab, team 3 BioPIC
French National Reference Centre for AL Amyloidosis and Other Monoclonal IG Deposition Diseases, University Hospital
University Hospital)
- Christophe Sirac
(University of Limoges, CRIBL lab, team 3 BioPIC
French National Reference Centre for AL Amyloidosis and Other Monoclonal IG Deposition Diseases, University Hospital)
Abstract
Immunoglobulin light chain (LC) amyloidosis (AL) is one of the most common types of systemic amyloidosis but there is no reliable in vivo model for better understanding this disease. Here, we develop a transgenic mouse model producing a human AL LC. We show that the soluble full length LC is not toxic but a single injection of pre-formed amyloid fibrils or an unstable fragment of the LC leads to systemic amyloid deposits associated with early cardiac dysfunction. AL fibrils in mice are highly similar to that of human, arguing for a conserved mechanism of amyloid fibrils formation. Overall, this transgenic mice closely reproduces human cardiac AL amyloidosis and shows that a partial degradation of the LC is likely to initiate the formation of amyloid fibrils in vivo, which in turn leads to cardiac dysfunction. This is a valuable model for research on AL amyloidosis and preclinical evaluation of new therapies.
Suggested Citation
Gemma Martinez-Rivas & Maria Victoria Ayala & Sebastien Bender & Gilles Roussine Codo & Weronika Karolina Swiderska & Alessio Lampis & Laura Pedroza & Melisa Merdanovic & Pierre Sicard & Emilie Pinaul, 2025.
"A mouse model of cardiac immunoglobulin light chain amyloidosis reveals insights into tissue accumulation and toxicity of amyloid fibrils,"
Nature Communications, Nature, vol. 16(1), pages 1-16, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-58307-2
DOI: 10.1038/s41467-025-58307-2
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-58307-2. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.